Wounds Therapeutic Pipeline H2 2014 Review in New Market Research Report

The Wounds Pipeline Review, H2 2014 therapeutic industry research report provides an overview of the Wounds therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Wounds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wounds and special features on late-stage and discontinued projects.
DALLAS, (informazione.it - comunicati stampa - salute e benessere)

The Wounds Pipeline Review, H2 2014 therapeutic industry research report provides an overview of the Wounds therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Wounds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wounds and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope of this research includes a snapshot of the global therapeutic landscape of Wounds, reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities, reviews key players involved in the therapeutics development for Wounds and enlists all their major and minor projects, summarizes all the dormant and discontinued pipeline projects, review of the Wounds products under development by companies and universities/research institutes based on information derived from company and industry-specific sources, Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, detailed assessment of monotherapy and combination therapy pipeline projects, Coverage of the Wounds pipeline on the basis of target, MoA, route of administration and molecule type and Latest news and deals relating related to pipeline products. Order a copy of this research at http://www.rnrmarketresearch.com/contacts/purchase?rname=239893 .

Companies involved in therapeutics development for Wounds and discussed in this research include Advancell, Aerpio Therapeutics, Inc., AlgiPharma AS, AndroScience Corporation, AnGes MG, Inc., APEIRON Biologics AG, Apricus Biosciences, Inc., Aridis Pharmaceuticals LLC, Beech Tree Labs, Inc., Bio3 Research S.r.l, Biotec Pharmacon ASA, Birken AG, Blueberry Therapeutics Ltd, CYATHUS EXQUIRERE PharmaforschungsGmbH, Dongkook Pharmaceutical Co., Ltd., Escape Therapeutics, Inc., GangaGen Inc., Garnet BioTherapeutics, Gene Signal International SA, GliaMed, Inc., HanAll Biopharma Co., Ltd., Hemostemix Ltd, Juventas Therapeutics, Inc., Karyopharm Therapeutics, Inc., Kasiak Research Pvt. Ltd., Kuros Biosurgery AG, Living Cell Technologies Limited, MediWound Ltd., Microbion Corporation, miRagen Therapeutics, Inc., Molecular Design International, Inc., Nabriva Therapeutics AG, NeoStem, Inc., Neumedicines Inc., Novan, Inc., Nuvo Research Inc., Octapharma AG, Omeros Corporation, Omnio Healer AB, Pacific Northwest Biotechnology, LLC, Pergamum AB, Pharming Group N.V.,  Regenics AS, RXi Pharmaceuticals Corporation, Sanofi, Sirnaomics, Inc., Smith & Nephew Plc, SomaGenics Inc., Stratatech Corporation, Sucampo Pharmaceuticals, Inc., Theravasc, Inc., Thesan Pharmaceuticals, Inc., Tissue Repair Company, vida therapeutics inc.

Global Markets Direct reports feature investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by an expert team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Reasons to buy Wounds - Pipeline Review, H2 2014 market research report:  

Explore more pharmaceuticals market research reports on wound care market at http://www.rnrmarketresearch.com/reports/life-sciences/biotechnology/wound-care .

About Us: 

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:   

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel:  +1-888-391-5441
[email protected]

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Slide ShowSlide Show
Non disponibili